Johnson & Johnson's market-leading LifeScan blood glucose monitor will be incorporated intothe remote controller for Insulet's next-generation OmniPod insulin pump.
Updated: February 17, 2012 10 a.m.
The next generation of Insulet's (NSDQ:PODD) OmniPod insulin pump, which is awaiting 510(k) clearance from the FDA, will be compatible with the LifeScan blood glucose monitoring technology made by Johnson & Johnson (NYSE:JNJ).
The 2 companies inked a deal for LifeScan's OneTouch technology to be incorporated into a new personal diabetes manager that patients use to control the OmniPod. Insulet's chief commercial officer, Peter Devlin, told MassDevice.com that the company is targeting a mid-2013 commercial release.
"It's essentially a new device that will require 510(k) clearance," Devlin explained. "By having the BGM integrated in the PDM, it simply makes that aspect of controlling your diabetes a bit easier."
Insulet already has a deal with Abbott (NYSE:ABT) and its FreeStyle BGM, but that pact is set to expire in 2013, he said. The OneTouch agreement with LifeScan runs through 2017 and has a trigger that would make it exclusive at Insulet's discretion, according to a press release.
Edwards Lifesciences CEO Michael Mussallem says the company now expects the FDA to approve its next-...
Reva Medical begins enrolling patients in Europe for a trial of its Fantom bioresorbable stent.
A subcommittee of the U.S. Senate's powerful Finance Committee holds a hearing on the medical device...
Zimmer Holdings and Biomet find a buyer for the knee and elbow assets they pledged to divest to...